Brought to you by 
Forest to develop Adamas’ memantine/donepezil combo for Alzheimer’s
04 Jun 2021
Executive Summary
Adamas Pharmaceuticals Inc. (optimized and controlled-release formulations of aminoadamantane compounds for CNS diseases) has licensed Forest Laboratories Inc. exclusive US development and marketing rights to its Phase III Arimenda, a fixed-dose, once-daily combination of extended-release memantine (which Forest sells as Namenda XR for moderate-to-severe Alzheimer’s disease) and immediate-release donepezil (Pfizer/Eisai’s Aricept) for moderate-to-severe dementia associated with Alzheimer’s.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest to develop Adamas’ memantine/donepezil combo for Alzheimer’s
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice